{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/EVMN",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Evommune, Inc. (NYSE: EVMN) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Evommune, Inc., listed on the NYSE under ticker EVMN, with ISIN US30054Y1073. The LEI is not on the record. The security type is Corporate, the segment is not on the record, and the sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 92 filings in the window 2025-11-08 to 2026-11-08, across 38 filing days. The filings comprise 42 directors' dealings, 20 regulatory filings, 11 corporate news, 8 prospectus, 8 results and 3 AGM/EGM filings. The median gap between filing days is 6 days. The latest filing is dated 2026-11-05 and is of type corporate news, 3 days before the record date. The NYSE median cadence gap is 6.0 days, with a median of 64.0 filings and a median latency of 4.0 days across 3,256 issuers. The sector median cadence gap is 6.0 days, with a median of 63.0 filings and a median latency of 4.0 days across 526 issuers.\n\n## Auditor\n\nThe auditor is not on the record, as the latest annual report cover carries no auditor name tag. The auditor location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds listing lines dated 2025-11-04 and 2025-11-05. It holds no delisting, no name change, and no segment move; the segment move is not on the record. The domicile change is not on the record. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as of 2026-11-04. The chapter's orderability section carries no client categories, so the outcome cannot name its client category.\n\n## Coverage\n\nThe issuer's investor-relations page names 13 research houses: Cantor, Clear Street, Evercore ISI, HC Wainwright, Leerink Partners, Morgan Stanley, Needham, Oppenheimer, Raymond James, RBC Capital Markets, Stifel, UBS and William Blair.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0002044725.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NYSE/EVMN (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.evommune.com/stock-data/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NYSE/EVMN (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/EVMN",
  "coverage": {
   "count": 13,
   "houses": [
    {
     "analyst": "Prakhar Aggarwal and Eric Schmidt",
     "house": "Cantor",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Kaveri Pohlman, PhD",
     "house": "Clear Street",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Gavin Clark-Gartner and Umer Raffat",
     "house": "Evercore ISI",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Mitchell Kapoor",
     "house": "HC Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Thomas Smith",
     "house": "Leerink Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Chris Yu, Executive Director",
     "house": "Morgan Stanley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Serge Belanger",
     "house": "Needham",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Kostas Biliouris, PhD",
     "house": "Oppenheimer",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Martin Auster",
     "house": "Raymond James",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Brian Abrahams",
     "house": "RBC Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Alex Thompson",
     "house": "Stifel",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Alice Nettleton",
     "house": "UBS",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Matt Phipps, Ph.D.",
     "house": "William Blair",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.evommune.com/stock-data/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.evommune.com/stock-data/analyst-coverage",
     "result": "read: 13 of 26 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 11,
    "directors_dealings": 42,
    "prospectus": 8,
    "regulatory_filing": 20,
    "results": 8
   },
   "cadence_median_gap_days": 6,
   "filing_days": 38,
   "filings": 92,
   "latency_days": 3,
   "latest": [
    {
     "category": "8-K",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000119312526448443/evmn-20261105.htm",
     "title": "8-K — 8-K (items 7.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "424B3",
     "date": "2026-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000119312526447627/evmn-2026-8k_project_daw.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    },
    {
     "category": "8-K",
     "date": "2026-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm",
     "title": "8-K — 8-K (items 1.01,3.02,7.01,8.01)",
     "type": "corporate_news"
    },
    {
     "category": "4",
     "date": "2026-10-15",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000162054826000009/xslF345X06/primarydocument.xml",
     "title": "4 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000119312526409865/evmn-20261001.htm",
     "title": "8-K — 8-K (items 7.01,9.01)",
     "type": "corporate_news"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/EVMN",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-09-23",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US30054Y1073"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002044725.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002044725.json",
    "state": "sourced",
    "value": "Evommune, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002044725.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002044725.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "EVMN"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [
    {
     "date": "2025-11-04",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000119312525264660/d80636d8a12b.htm",
     "title": "8-A12B — 8-A12B"
    },
    {
     "date": "2025-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/2044725/000087666125000841/EVMN110525.pdf",
     "title": "CERT — NYSE CERTIFICATION"
    }
   ],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:fc60b980fbd1a43a6d321d92321a691a9df32b0648f3830ef031fa3029f48f41",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/EVMN",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:fc60b980fbd1a43a6d321d92321a691a9df32b0648f3830ef031fa3029f48f41",
 "path": "/us/NYSE/EVMN",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Evommune, Inc., listed on the NYSE under ticker EVMN, with ISIN US30054Y1073. The LEI is not on the record. The security type is Corporate, the segment is not on the record, and the sector is 2834 Pharmaceutical Preparations. The jurisdiction is United States, Delaware. The status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 92 filings in the window 2025-11-08 to 2026-11-08, across 38 filing days. The filings comprise 42 directors' dealings, 20 regulatory filings, 11 corporate news, 8 prospectus, 8 results and 3 AGM/EGM filings. The median gap between filing days is 6 days. The latest filing is dated 2026-11-05 and is of type corporate news, 3 days before the record date. The NYSE median cadence gap is 6.0 days, with a median of 64.0 filings and a median latency of 4.0 days across 3,256 issuers. The sector median cadence gap is 6.0 days, with a median of 63.0 filings and a median latency of 4.0 days across 526 issuers.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, as the latest annual report cover carries no auditor name tag. The auditor location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds listing lines dated 2025-11-04 and 2025-11-05. It holds no delisting, no name change, and no segment move; the segment move is not on the record. The domicile change is not on the record. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as of 2026-11-04. The chapter's orderability section carries no client categories, so the outcome cannot name its client category.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 13 research houses: Cantor, Clear Street, Evercore ISI, HC Wainwright, Leerink Partners, Morgan Stanley, Needham, Oppenheimer, Raymond James, RBC Capital Markets, Stifel, UBS and William Blair.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0002044725.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/EVMN"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.evommune.com/stock-data/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/EVMN"
  }
 ],
 "title": "Evommune, Inc. (EVMN) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}